Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YB1-X7 Injection in Advanced Hepatocellular Carcinoma After Failure of First-Line Therapy
ChiCTR2600124549Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- May 2026
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Oncolytic Bacteria → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of YB1-X7 in hepatocellular carcinoma (HCC) (5 cohorts), sponsored by Shanghai General Hospital. Primary endpoints: Dose-Limiting Toxicity (DLT) Incidence Rate, Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
YB1-X7
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600124549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124549.